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ABSTRACT: Ebola virus disease is caused by Ebolavirus infection. Within infection, Ebola nucleoprotein 
(EBOV NP) is essential part for virus proliferation. Recent report showed that the outbreak was hap-
pened in Congo on February 2021. Although million cases were reported, the drug is remain unavai-
lable. However, Indonesia had a high diversity of plants as traditional drugs. This research aimed to 
identify the traditional drug plants as potential inhibitor for EBOV NP. The SMILE notation of 65 identi-
fied compounds were collected from PubChem and 3D structured of EBOV NP (PDB ID: 4Z9P) was ob-
tained from PDB. Molecular docking was conducted between selected compounds and EBOV NP. Clabis-
trin C was selected as a control. Complex of compounds-EBOV NP and its amino acid residues were de-
picted by using Chimera X and LigPlot. Several potential compounds were selected for pharmacological 
activity prediction by PASS Online, toxicity analysis by ProTox-II, and drug likeness analysis with SWIS-
SADME. Result showed that among the docked compound, hesperidin, cucurbitacin, ginsenoside RH2, 
and ginsenoside RO had lower binding energy compared to control. Moreover, all of those compounds 
had comparable hydrogen and hydrophobic interactions with EBOV NP. Further analysis showed it has 
potential biological function for Ebola disease, such as antiviral, antioxidant, and immunostimulant. All 
those compounds had low toxicity. As conclusion, there are four promising compounds that potentially 
inhibited the Ebolavirus proliferation.
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1. Introduction
Ebola viruses are negative stranded RNA vi-
ruses that belong to the Filoviridae family and it 
is endemic to regions of west and equatorial Afri-
ca. It known by primarily transmitted by human-
to-human contact with infected body fluids and 
corpses [1]. Ebolaviruses were first identified in 
1976, over 41 outbreaks of Ebola disease have 
been identified in sub-Saharan Africa, mostly in 
Sudan, Uganda, Democratic Republic of Congo, 
and Gabon. Until 2020, there was 34,644 cases 
and 14,987 deaths around the world. In the latest 
outbreak in the 14 February 2021 at guinea, the 
cases showed symptoms of diarrhea, vomiting 
and bleeding. Other cases showed that among the 
7 other cases, five have died (4 probable and 1 
confirmed with ebola virus) and the others were 
still in the isolation at dedicated health care facili-
ties [2]. 
Ebola Nucleocapsid RNA is complexed with 
the NP, VP35, VP30, and L proteins [3]. The in-
fection mechanism of Ebola virus was started by 
targeting the immune cells like endothelial cells, 
liver cells, and several types of immune cells. 
When the virus keep growing were lead to injury 
to the blood vessels, it could induce the blood clot 
and liver damage [4]. Ebola virus nucleoprotein 
(EBOV NP) were one of the protein that respon-
sible in viral transcription and replication by di-
rect interaction with EBOV RNA, VP35, and tran-
scription regulator VP30 [5].  In particular, recent 
results have clearly demonstrated that viral NP 
could be directly used as the target for antiviral 
development [6] and raising a great potential 
to find new antiviral agents. Various secondary 
metabolites derived from traditional medicinal 
plants is considered for having huge potential to 
be developed as antiviral drug. Therefore, this 
research aimed to investigate the secondary me-
tabolites from Indonesian traditional medicinal 
drug which had potential ability to be developed 
as antiviral drug for Ebola disease.
2. Materials and method
2.1. Sample preparation
Sixty five active compounds data of traditional 
drugs plants in Indonesia were obtained from 
PubChem database (https://pubchem.ncbi.nlm.
nih. gov/). Calbistrin C was selected as referenced 
compound. In brief, previous research showed 
that it had low binding affinity about -7.9228 
kcal/mol and RMSD value 2.3913 [7]. Further-
more, the ID number of each compound and nota-
tion of canonical simplified molecular-input line-
entry system (SMILES) was collected for further 
analysis. Furthermore, the 3D structure of each 
compound was collected in sdf format. The pro-
cess of minimization was conducted by using the 
Open Babel plug-in within PyRx software. It was 
essential for preparing compound as ligand for 
molecular docking analysis. The 3D structure of 
Ebola virus nucleoprotein (EBOV NP) protein was 
obtained from the Protein Data Bank (PDB) data-
base (https://www.rcsb.org/) with PDB ID 4Z9P. 
The unnecessary molecules including water was 
removed from EBOV NP structure by using Chi-
mera. Furthermore, protein structure was added 
by hydrogen as preparation for further analysis. 
2.2. Molecular docking simulation and visualiza-
tion of complex ligands-EBOV NP
The interaction prediction between EBOV NP 
and 65 ligands were conducted by using molecu-
lar docking analysis. The process performed by 
using Autodock Vina on the Pyrx software. Dock-
ing process was addressed to the specific site of 
EBOV NP. Furthermore, the binding affinity score 
was collected and compared to get the potential 
candidate of drug compound. The complexes of 
EBOV NP and potential ligands were visualized 
by using Chimera software and analyzed by using 
LigPlot software to identify the amino acid resi-
dues interaction.
2.3. Pharmacokinetic prediction of potential li-
gands
Four potential compounds as result of mo-
lecular docking were listed and analysed based 
on the Lipinski rule of 5. The canonical SMILE of 
each potential compounds was analysed by using 
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SWISS ADME (http://www.swissadme.ch/) [8]. 
Furthermore, the analysis result of each compo-
nent Lipinski rule of 5 were collected.
2.4. Pharmacological activity prediction of po-
tential ligands
The pharmacological activity of selected po-
tential compounds were identified by using PASS 
Online webserver (http://way2drug.com/pass-
online/). Various pharmaceutical activity was 
analyzed based on score of probability of acti-
vity (Pa) and probability of inactivity (Pi). The Pa 
score was varied from 0-1 which suggested the 
level activity of compounds [9,10].
2.5. Toxicity prediction of potential ligands
Selected potential compounds were addressed 
for toxicity prediction. Analysis was performed 
by using ProTox-II (https://tox-new.charite.de/
protox_II/) by submitting the canonical SMILE of 
each compound [11]. Result of analysis was de-
termined the compounds into six class of toxicity.
3. Result and discussion
Sixty-five ligands in this study are obtained 
from various traditional plants in Indonesia 
which believed had an antiviral function by an-
cestors. As tropical country, Indonesia is conside-
red as mega-diversity country in fauna and flora 
diversity. Various plants were found in Indonesia 
so that it considered by having huge potential to 
be developed for pharmaceutical function [12]. 
Therefore, there are many Indonesian people 
that utilizing plants as medicine so that it known 
as traditional drug plants. It believed safe and 
culturally acceptable. In brief, all those ligands 
samples could be isolated range from cucurbita-
ceous plants, ginseng, tea, pepper, pomegranate 
[13-17].
Ebola virus nucleoprotein (EBOV NP) is pro-
tein which had essential function for virus re-
plication. It consists of 739 amino acid residues 
and it has structure which could be divided into 
N-tail, N-lobe, C-lobe, and C tail. Moreover, it 
could mediate the process during virion trans-
cription process and protect the RNA genome 
from de-gradation. EBOV NP is also known for 
contri-buting into budding and assembly process 
within viral life cycle. Therefore, it become an at-
tractive target for drug development [18]. Study 
of interaction of protein EBOV NP-ligand was de-
monstrated by using molecular docking analysis. 
The docking process was addressing all ligands 
to bind into specific site with coordinate center 
X: 6.9108, Y: 11.1981, Z: 3.5358; and dimensions 
(angstrom) X: 19.1764, Y: 23.8639, Z: 24.8673 
(Figure 1). This process was aimed to predict the 
ability of the ligands extracted from various tra-
ditional medicinal plants to bind and inhibit the 
activity of EBOV NP. The ability of ligand to bind 
into protein was demonstrated by the binding af-
finity score. Negative score is defined as strong 
interaction between ligands and protein.
The utilization of various traditional drug 
compounds as inhibitor candidate of EBOV NP 
showed that 17 active compounds had lower 
binding energy as compared to control, then top 
four compounds with the lowest binding energy 
were taken for visualization and further analysis 
(Table 1). In brief, hesperidin, cucurbitacin, Gin-
senoside RH2 and Ginsenoside RO had binding 
affinity score about -7,6 kcal/mol, -7,6 kcal/mol, 
-7,5 kcal/mol, and -7,4 kcal/mol, respectively. 
Those four ligands showed lower binding affini-
ty as compared to the Calbistrin C with score -6,4 
kcal/mol. Calbistrin C (ZINC4262121) was de-
monstrated as the best ligand from previous ana-
lysis that bind to EBOV NP. Therefore, it is chosen 
as compound reference in this research.
Figure 1 showed that all ligands were bound 
into the same location with the native ligand. 
Moreover, those ligands also successfully formed 
hydrogen and hydrophobic bond within the bin–
ding pocket of EBOV NP. Complex of EBPV NP-po-
tential ligands was addressed for amino acid resi-
due analysis. Results demonstrated that all those 
ligands could form hydrogen bond and hydropho-
bic interactions in the binding pocket of EBOV NP 
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Figure 1. Ligands Hesperidin (red), Cucurbitacin (orange), Ginsenoside RH2 (purple blue), Ginsenoside RO 
(wheat), and reference compound Calbistrin C (cyan) were bind into specific site of EBOV NP
Figure 2. Amino acid residues within EBOV NP with potential ligands, including Calbistrin C (A), 





(Figure 2). Each of potential ligands shared com-
parable amino acid residues which similar to the 
Calbistrin C, including Arg240, and Arg298. Hes-
peridin had hydrogen bonds with Gln238, and 
His310, while cucurbitacin had hydrogen with 
Lys160 (Table 2).
Further analysis was conducted by addressing 
those four potential ligands to the pharmacoki-
netics and toxicity investigation. There are cer-
tain criteria of pharmacokinetics and drug like-
ness of compound so that it could be developed as 
drug candidate. It defined as Lipinski rule of five 
which originally proposed by Lipinski. In brief, 
the Lipinski’s rule of five is including criteria such 
as molecular weight less than 500 g/mol, H-bond 
donor more than 5, H-bond acceptor less than 
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Table 1. The result of binding affinity score between sixty five potential ligands and EBOV NP
No PubChem ID Compound Binding Energy  
(kcal/mol) 
1 10621 Hesperidin -7.6 
2 119287 Cucurbitacin -7.6 
3 119307 Ginsenoside RH2 -7.5 
4 11815492   Ginsenoside RO -7.4 
5 275182 Berbamine -7.3 
6 64945 Ursolic Acid -7.3 
7 65064 Epigallocathechin gallate -7.3 
8 11787114 Silvestrol -7.2 
9 64971 Betulinic Acid -7.2 
10 1794427 Chlorogenic Acid -6.8 
11 6918670 Ingenol Mebutate -6.8 
12 3213 Ellipticine -6.7 
13 5287969 Flavopiridol -6.7 
14 12855889   ginsenoside RC -6.7 
15 3220 Emodin -6.5 
16 969516 Curcumin -6.5 
17 5280343 Quercetin -6.4 
18 6474046 Calbistrin C (reference control) -6.4 
19 5280863 Kaempferol -6.2 
20 9064 Catechin -6.2 
21 5281654 Isorhamnetin -6.1 
22 5281708 Daidzein -6.1 
23 638024 Piperine -6.1 
24 5280961 Genistein -6.0 
25 6928 2,2’-metilen bis[6-(1,1- dimetiletil)-4-etil] fenol -6.0 
26 5351344 Combretastatin -5.9 
27 3885 Beta-Lapachone -5.8 
28 285033 Homoharingtonie -5.6 
29 370 Gallic acid -5.3 
30 91354 Aromadendrene -5.2 
31 5281794 6-shogaol -5.1 
32 72 Protocatechuic -5.0 
33 2519 Caffein -4.9 
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No PubChem ID Compound Binding Energy  
(kcal/mol) 
34 6508206 α-humulene -4.9 
35 689043 Caffeic Acid -4.9 
36 111037 alpha-Terpinyl acetate -4.8 
37 4276 Myristicin -4.8 
38 445858 Ferulic acid -4.8 
39 521214 junipper-campor -4.8 
40 10742 Syringic acid -4.7 
41 3026 Dibutil ftalat -4.7 
42 637542 P-Coumaric Acid -4.7 
43 643820 Nerol -4.7 
44 6651 Terpin -4.7 
45 8468 Vanillic acid -4.7 
46 5280450 9,12-Asam Oktadeka Dienoat (lionelic acid) -4.6 
47 5281783 etl p-metoksi sinamat -4.6 
48 17100 Alpha terpineol -4.5 
49 18818 Sabinene -4.5 
50 91749664 2alpha,9-Dihydroxy-1,8-cineole -4.5 
51 11148 Trimiristin -4.5 
52 10819 Perillyl Alcohol -4.4 
53 3314 Eugenol -4.4 
54 36284 4-Ipomeanol -4.4 
55 7460 1-Phellandren -4.4 
56 14896 beta Pinene -4.3 
57 26447 menthone -4.3 
58 590536 2-isopropylbenzaldehyde -4.3 
59 6616 camphene -4.3 
60 7463 p-cimene, -4.3 
61 985 Asam palmitat -4.3 
62 1254 Menthol -4.2 
63 22311 limonene -4.2 
64 8748 beta-terpineol -4.2 
65 11005 Myristic Acid -4.1 
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Table 2. List of amino acid residues within complex of EBOV NP and potential ligands
Ligands Hydrogen bonds Hydrophobic interactions 
Hesperidin Gln238: 3.07, 3.10, & 2.87 Å 
Arg240: 3.10 & 2.70 Å 
His310: 3.07 Å 
Lys160, Val163, Lys171, Ala239, 
Phe241,Ser242, Gly243, Leu244, 
Leu245,Lys248,Glu309. 
Cucurbitacin Lys160: 3.27 Å  
Phe241: 3.26 Å 
Pro159, Val163,Ser242, Gly243, 
Leu245,Lys248, Arg298, Glu309, His310. 
Ginsenoside RH2 Phe241: 3.14 Å;  
Gly243: 2.81 Å 
Leu245: 3.02 Å;  
Lys248: 2.90 Å 
Arg298: 3.13 & 3.15 Å 
Pro159, Lys160, Val163, Lys171, Gln238, 
Ser242, Leu244, Leu308, Glu309, His310. 
Ginsenoside RO Pro159: 2.70 Å;  
Arg240: 3.14 Å 
Ser242: 3.15 Å;  
Gly243: 3.00 &2.73 Å 
Arg298: 2.99 &2.95 Å;  
Leu308: 3.02 Å 
Gly311: 3.02 Å 
Lys160, Val163, Phe241, 
Leu245,Lys248,Glu309, His310. 
Calbistrin C Pro159: 3.13 Å;  
Lys160: 3.04 & 3.34 Å 
Gln238: 2.84 Å;  
Gly243: 3.07 Å 
Leu308: 3.24 Å;  



















1	 Hesperidin	 610.56	 15	 8	 141.41	 -3.04	 NO	
2	 Cucurbitacin	 498.65	 6	 2	 138.22	 2.24	 YES	
3	 Ginsenoside	Rh	 622.87	 8	 6	 172.26	 2.55	 NO	
4	 Ginsenoside	Ro	 957.11	 19	 11	 234.00	 -1.41	 NO	




10, Log P less than 5, and molar refractivity bet-
ween 40-130 [19]. Among those criteria, both of 
H-bond donor and acceptor contributed a crucial 
function for determining the specificity of ligand 
binding. Therefore, the drug compound could be 
assured to bind into specific target [20,21]. Re-
sult showed that only cucurbitacin which accom-
plished all the criteria (Table 3). It demonstrated 
by each criteria which belong to the Lipinski rule 
of five standard. Moreover, toxicity of all potential 
ligands were investigated. 
Analysis of pharmacological activity showed 
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Table 4. Pharmacological activity of potential ligands
No CID Compounds Pa score Pi score Activity 
1 10621 Hesperidin 0.846 0.003 Antioxidant 
   0.487 0.039 Immunostimulant 
   0.193 0.102 Antiviral 
2 119287 Cucurbitacin 0.286 0.101 Antiviral 
   0.275 0.029 Antioxidant 
3 119307 Ginsenoside RH2 0.900 0.004 Immunostimulant 
   0.660 0.004 Antioxidant 
   0.237 0.068 Antiviral 
4 11815492 Ginsenoside RO 0.912 0.003 Immunostimulant 
   0.686 0.004 Antioxidant 
   0.303 0.035 Antiviral 
5 6474046 Calbistrin C 0.251 0.036 Antioxidant 




Table 5. Toxicity class of potential ligands
that most of all selected compound had ability as 
an antiviral and immunostimulant. The predicted 
activity level was varied based on the probability 
of activity (Pa) score. Ginsenoside RH2 and gin-
senoside RO had slightly higher of potential ac-
tivity as antiviral as compared with the control 
(Calbistrin C). In brief, Ginsenoside RH2 and gin-
senoside RO had Pa score about 0.237 and 0.303 
while calbistrin c had Pa score about 0.172. Fur-
ther interesting result exhibited that hesperidin, 
ginsenoside RH2, and ginsenoside RO had func-
tion as immunostimulant with Pa score 0.487, 
0.900, and 0.912, respectively. Whilst calbistrin C 
had lack of immunostimulant activity (Table 4). 
Score of Pa demonstrated the activity level of se-
lected compound based on the study which held 
by related research. Score of Pa < 0.7 suggested 
high potential of compound, while 0.5 < Pa < 0.7 
exhibited moderate potential of compound, and 
Pa < 0.5 showed poor potential of compound 
[22]. Therefore, it demonstrated that hesperi-
dine, ginsenoside RH2, and ginsenoside RO had 
a potential function as candidate of antiviral and 
immunostimulant for Ebola virus disease treat-
ment. It is in line with the pathology of Ebola vi-
rus which started by targeting and damaging the 
immune cells [4].
Analysis was conducted by using ProTox-II 
No CID Compounds LD50 (mg/kg) Tox Class Acc (%) 
1 10621 Hesperidin 12000 6 72.9 
2 119287 Cucurbitacin 100 3 68.07 
3 119307 Ginsenoside RH2 4000 5 70.97 
4 11815492 Ginsenoside RO 3220 5 72.9 
5 6474046 Calbistrin C 1190 4 100 
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webserver which helped to determine the toxi-
city class of each ligand. Result showed that all 
of ligands had different toxicity class. Hesperi-
din belongs to the higher toxicity class with LD50 
12.000 mg/kg, while cucurbitacin belongs to the 
lowest toxicity class with LD50 100mg/kg. It could 
be concluded that hesperidin administration is 
estimated safer than cucurbitacin. How-ever, all 
of those potential ligands had possibility to be de-
veloped as drug compound (Table 5).
4. Conclusion
Ebola virus diseases is manifestation of di-
sease which caused by infection of Ebola virus. It 
consists of various part of body structure, inclu–
ding Ebola virus nucleoprotein (EBOV NP) which 
had essential function for viral replication. Sixty 
five natural products or secondary metabolite 
derived from various traditional medicinal plants 
in Indonesia is analyzed to identify the most po-
tential candidate for antiviral drug development. 
Result showed that there are four secondary me-
tabolites with the lowest binding affinity score as 
compared to the Calbistrin C as reference com-
pound, such as hesperidin, cucurbitacin, ginse-
noside RH2, and ginsenoside RO. Further analysis 
including pharmacokinetics, drug likeness, phar-
macological activity, and toxicity analysis also 
showed that all those four compounds are the 
most potential candidate for antiviral drug de-
velopment. It could be collected from citrus, tea, 
and cucurbitaceae plants.
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